Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion.
- Journal:
- Diabetes Care
- Published:
- DOI:
- 10.2337/dc25-2294
- Affiliations:
- 3
- Authors:
- 7
| Institutions | Authors | Share |
|---|---|---|
| Lilly, United States of America (USA) | 0.57 | |
| LMC Healthcare, Canada | 0.21 | |
| York University, Canada | 0.21 |